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Abstract
Background: Myocardial involvement in AAV patients might be silent, presenting with no or nonspecific symptoms,
normal ECG, and preserved left-ventricular ejection fraction (LV-EF). Since up to 50% of deaths in these patients may be
due to myocardial involvement, a reliable diagnostic tool is warranted. In contrast to LGE-CMR, which has its strengths
in detecting focal inflammatory or fibrotic processes, recent mapping techniques are able to detect even subtle, diffuse
inflammatory or fibrotic processes. Our study sought to investigate ANCA (antineutrophil cytoplasmic antibody)
associated vasculitides (AAV) patients for myocardial involvement by a cardiovascular magnetic resonance (CMR)
protocol, including late gadolinium enhancement (LGE) and mapping sequences.
Methods: Thirty seven AAV patients were prospectively enrolled and underwent CMR imaging. Twenty healthy
volunteers served as controls.
Results: Mean LV-EF was 64%; LGE prevalence of the AAV patients was 43%. AAV patients had higher median
native T1 (988 vs. 952 ms, p < 0.001), lower post-contrast T1 (488 vs. 524 ms, p = 0.03), expanded extracellular
volume (ECV) (27.5 vs. 24.5%, p < 0.001), and higher T2 (53 vs. 49 ms, p < 0.001) compared to controls, with most
parameters independent of the LGE status. Native T1 and T2 in AAV patients showed the highest prevalence of
abnormally increased values beyond the 95% percentile of controls.
Conclusion: AAV patients demonstrated increased T1, ECV, and T2 values, with native T1 and T2 showing the
highest prevalence of values beyond the 95% percentile of normal. Since these findings seem to be independent
of LGE, mapping techniques may provide complementary information to LGE-CMR in the assessment of myocardial
involvement in patients with AAV.
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Background
ANCA (antineutrophil cytoplasmic antibody)-associated
vasculitides (AAV) comprise different types of auto-
immune diseases, in which autoantibodies react to
proteinase 3 (PR3), or myeloperoxidase (MPO) [1]. As
systemic disorders, necrotizing granulomatous lesions
may occur in any organ, including the myocardium [2].
EGPA (eosinophilic granulomatosis with polyangiitis,
formerly known as Churg-Strauss syndrome) and GPA
(granulomatosis with polyangiitis, formerly known as
Wegener’s granulomatosis) are both subtypes of AAV.
The prevalence of myocardial involvement varies, ranging
from 16 to 92% in EGPA, and 6 to 86% in GPA patients
[3], depending on different diagnostic methods and dis-
ease activity. Patients with myocardial involvement may
have no or nonspecific symptoms, normal ECG, and pre-
served left-ventricular ejection fraction (LV-EF) yet they
may nevertheless face life-threatening arrhythmias or end-
stage heart failure during the course of the disease [4, 5].
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EGPA patients frequently show myocardial granulomas
and severe tissue alterations on histopathology [6], and
up to 50% of patients die of cardiac causes [7]. This is
also true in GPA patients [8]. Since myocardial involve-
ment might be reversible if prompt adequate treatment
is initiated [9], a reliable tool for the early detection of
myocardial involvement is warranted. Cardiovascular
magnetic resonance (CMR) offers not only functional
assessment but also excellent tissue characterization by
the use of late gadolinium enhancement (LGE) [10].
However, LGE is known to perform best in the detec-
tion of focal myocardial processes rather than diffuse fi-
brotic or inflammatory processes [11]. T1 and T2
mapping could already prove their diagnostic value in
the detection of both focal and diffuse myocardial alter-
ations in various cardiomyopathies, including cardiac
involvement in rheumatic disorders [12, 13] or inflam-
matory cardiomyopathies [14], and therefore might be
appropriate tools to complement LGE-CMR.
Consequently, aim of our study was to evaluate sys-
tematically EGPA and GPA patients for myocardial in-
volvement by a dedicated CMR protocol, including LGE,
T1 and T2 mapping.
Methods
Patient population
Thirty-seven patients were prospectively enrolled be-
tween September 2013 and February 2016 if they ful-
filled the following criteria: 1) Diagnosis of EGPA or
GPA according to the revised Chapel Hill Consensus
Conference nomenclature [15]; and 2) no history of
CAD, myocardial infarction and/or prior revasculariza-
tion; and 3) successful CMR.
Sex and age-matched healthy volunteers (n = 20) with
no history of inflammatory and cardiovascular disease
served as control group. All participants provided a
blood sample for measurement of hematocrit. All pa-
tients gave written informed consent, and the study
protocol was approved by the local ethics committee.
CMR protocol
ECG gated CMR was performed in breath-hold using a
1.5 T Aera (Siemens, Erlangen, Germany) in line with
current recommendations [16]. Cine was performed
using a steady-state free-precession (SSFP) sequence.
LGE images were acquired on average 5–10 min after
contrast, using a segmented inversion recovery gradient
echo (IR-GRE) sequence [10]. The contrast dose (gado-
pentetate) was 0.15 mmol/kg.
A modified Look-Locker inversion recovery prototype
sequence (MOLLI) was used for T1 mapping and per-
formed in a single midventricular short-axis (SAX) slice
at mid-diastole, prior to and 20 min after contrast [17].
Short-axis T2 mapping was performed in the corre-
sponding midventricular SAX before administration of
contrast agent using an ECG-triggered T2-prepared
single-shot bSSFP prototype sequence with multiple T2
preparation times [18].
More detailed information on CMR protocol is pro-
vided in the Additional file 1.
CMR analysis
Cine and LGE images were evaluated by experienced
observers (S.G., H.M.) as described elsewhere [10]. Ex-
tent of LGE (expressed as percentage of myocardial
mass) was assessed using QMass software (Medis, Leiden,
The Netherlands). The distribution of LGE was character-
ized as epicardial, intramural, transmural, or subendocar-
dial [10].
Color-coded T1, ECV, and T2 maps were generated
based on inline-generated, motion-corrected raw images
using QMap software 1.0 (Medis, Leiden, the Netherlands)
in a single matching midventricular SAX. Motion-cor-
rected T1 maps were examined for quality in three
modalities: 1) raw T1 images 2) T1 maps 3) R2 maps.
Endo- and epicardial contours were manually drawn
by two experienced observers (S.G., A.M.), and then
divided into 6 segments using the anterior right-
ventricular insertion point as reference. Care was
taken to avoid partial-volume effects at the endocar-
dial and epicardial borders for T1, ECV and T2 maps.
Global T1, ECV, and T2 values were calculated: T1
values were determined by fitting an exponential
model to the measured data [19]. The hematocrit
allowed with native and post-contrast T1 measure-
ments of the myocardium and blood pool the calcula-
tion of extracellular volume (ECV), using a previously
described equation [20]. T2 results were obtained by
fitting a 2-parameter intensity-weighted exponential
model (no offset term) [21].
Evaluation of disease activity
The Birmingham Vasculitis Activity Score (BVAS) is a
validated tool for assessment of disease activity in pa-
tients with different forms of vasculitis. The score in-
cludes items grouped into 9 organ systems, only features
of active vasculitis are counted. BVAS separates symp-
toms that are new or worse from those that are persist-
ent. Remission is defined as BVAS of 0, whereas active
disease means BVAS ≥1 [22].
Statistical analysis
Absolute numbers and percentages were computed to
describe the patient population. Normally distributed
continuous variables were expressed as means (with
standard deviation) and skewed variables were presented
as medians (with quartiles). Comparisons between groups
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were made using the Mann-Whitney U test or the Fisher’s
exact test, as appropriate. P-values (two-tailed) of <0.05
were considered significant. All statistical analyses were




In total, n = 57 subjects were included in this study
(Table 1): n = 37 AAV patients (22 EGPA, 15 GPA), n = 20
controls. At inclusion, AAV patients were 55 ± 16 years of
age, predominantly female (65%), and did not differ sig-
nificantly to controls for age and gender (p = 0.52 p = 0.69,
respectively).
Non-specific dyspnea was reported in 43%, other symp-
toms were rare. ECG abnormalities were detected in 30%
(n = 11). Median time of disease duration was 3 years; all
patients were on steroids during the time of CMR.
Dividing AAV patients in LGE-positives and LGE-
negatives revealed similar baseline characteristics between
both groups, Table 2.
General CMR results
The mean LV-EF was 64% and did not differ from the
control group (p = 0.84), Table 3. Functional CMR pa-
rameters were similar between AAV patients and con-
trols. LGE was present in 16 (43%) of the AAV group,
most commonly occurring in a non-ischemic pattern.
All controls were LGE-negative. Dividing patients by
LGE status revealed that LV-EF was lower, but still pre-
served, in LGE-positive AAV patients vs. LGE-negative
patients (59% vs. 69%, p = 0.01), Table 4.
CMR findings of EPGA and GPA subgroups can be
viewed in Tables 5 and 6.
T1 and ECV results
We found higher native T1 values in AAV patients than in
controls: 988 (965–1017) vs. 952 (923–960) ms, p < 0.001;
Table 3/Fig. 1. Post-contrast T1 values were decreased in
comparison to controls: 488 (468–528) vs. 524 (500–529)
ms, p = 0.03, Table 3/Fig. 1. For T1-derived extracellular
volume fraction (ECV), AAV patients demonstrated sig-
nificantly higher values: 27.5 (26–29) % vs. 24.5 (23–25) %
in the control group, p < 0.001, Table 3/ Fig. 1. T1 (native
and post-contrast) and ECV values did not correlate with
disease activity (BVAS), p = 0.38, p = 0.09, p = 0.21,
respectively.
LGE-positive patients showed no significant differences
in native T1 and ECV compared to LGE-negative patients
(p = 0.10, p = 0.13, respectively), whereas post-contrast T1
values were significantly lower in LGE-positive pa-
tients (p = 0.04), Table 4.
Subgroup analysis revealed that, compared to healthy
controls, EGPA patients demonstrated: 1) significantly







Age (yrs) 55 ± 16 54 ± 16 55 ± 16
Gender (male) 13 (35%) 5 (23%) 8 (53%)
Cardiovascular risk factors
Diabetes 7 (19%) 5 (23%) 2 (13%)
Hypertension 13 (35%) 8 (36%) 5 (33%)
Smokingb 13 (35%) 7 (32%) 6 (40%)
Hyperlipidemia 6 (16%) 5 (23%) 1 (7%)
Family history of CVD 11 (30%) 8 (36%) 3 (20%)
Obesity (BMI≥ 30 kg/m2) 9 (24%) 5 (23%) 4 (27%)
Symptoms (multiple possible)
Angina 6 (16%) 4 (18%) 2 (13%)
Dyspnea 16 (43%) 12 (54%) 4 (27%)
Palpitations 4 (11%) 4 (18%) -
Syncope 1 (3%) 1 (5%) -
ECG abnormality 11 (30%) 9 (41%) 2 (13%)
Years since diagnosis
3 (0–11) 4 (0–11) 2 (0–11)
< 1 12 (32%) 6 (27%) 6 (40%)
1–4 11 (30%) 5 (23%) 6 (40%)
5–9 11 (30%) 10 (46%) 1 (7%)
≥ 10 3 (8%) 1 (5%) 2 (13%)
Disease Activity
BVAS 5.5 (1–14) 5 (3–8) 11.5 (0–24)
Hematocrit 0.39 (0.36–0.42) 0.4 (0.38–0.42) 0.38 (0.32–0.42)
Medication
Beta-blockers 9 (24%) 6 (27%) 3 (20%)
ARB 14 (38%) 7 (32%) 7 (47%)
ASA 5 (14%) 5 (23%) -
CCB 8 (22%) 4 (18%) 4 (27%)
Statins 3 (8%) 2 (9%) 1 (7%)
Diuretics 8 (22%) 7 (32%) 1 (7%)
Steroids 37 (100%) 22 (100%) 15 (100%)
NSAID 1 (3%) 1 (5%) -
Antibodies 2 (5%) 1 (5%) 1 (7%)
Cyclophosphamide 17 (46%) 4 (18%) 13 (87%)
Azathioprine 4 (11%) 2 (9%) 2 (13%)
Methotrexate 5 (14%) 4 (18%) 1 (7%)
All values are n (%) or mean ± SD or interquartile ranges. apercentages based
on number of EGPA/GPA patients, respectively, bcurrent or ever-smokers. EGPA
eosinophilic granulomatosis with polyangiitis, GPA granulomatosis with polyan-
giitis, CVD cardiovascular disease, BMI body mass index, ECG electrocardio-
gram, BVAS Birmingham vasculitis activity score, ARB angiotensin receptor
blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonste-
roidal anti-inflammatory drug
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higher median native T1 (p = 0.003) and ECV values
(p < 0.001), 2) significantly decreased post-contrast
values (p = 0.02), Table 5. Among patients with GPA,
we found increased medians for native T1 and ECV
values (both p < 0.001), but no significant difference
for post-contrast T1, p = 0.16, Table 6.
Comparing EGPA vs. GPA patients revealed no signifi-
cant differences in native T1, post-contrast T1 and ECV
(p = 0.09, p = 0.32, p = 0.44, respectively).
T2 results
Higher median myocardial T2 values were reported in
AAV patients compared to controls: 53 (51–55) vs. 49
(48–51) ms, p < 0.001, Table 3/Fig. 1. LGE-negative
patients showed a median of 51 (50–55) ms, and
LGE-positive patients of 54 (52–56) ms, p < 0.001
each, also see Table 4. Similar to T1, T2 values did
not correspond to the patients disease activity
(BVAS), p = 0.89.
In the subgroup analysis, T2 values for both EGPA
and GPA patients differed significantly from the T2
values of the control group (p < 0.001 each), Tables 5
and 6. In contrast, T2 values between EGPA and GPA
showed no significant difference (p = 0.85).
Figure 2 displays a female EGPA LGE-positive
patient with increased native T1, ECV, and T2, and
decreased post-contrast T1. Figure 3 illustrates a
LGE-negative EGPA patient with increased T1, ECV,
and T2 values.







Diabetes 3 (14%) 4 (25%) 0.41
Hypertension 8 (38%) 5 (31%) 0.67
Smokinga 8 (38%) 5 (31%) 0.98
Hyperlipidemia 2 (10%) 4 (25%) 0.21
Family history of CVD 6 (29%) 5 (31%) 0.86
Obesity (BMI ≥ 30 kg/m2) 6 (29%) 3 (19%) 0.49
Symptoms (multiple possible)
Angina 2 (10%) 4 (25%) 0.21
Dyspnea 8 (38%) 8 (50%) 0.55
Palpitations 2 (10%) 2 (13%) 0.72
Syncope - 1 (6%) 0.25
ECG abnormality 5 (24%) 6 (38%) 0.37
Years since diagnosis
< 1 8 (38%) 4 (25%) 0.57
1–4 5 (24%) 6 (38%) 0.63
5–9 7 (33%) 4 (25%) 0.67
≥ 10 1 (5%) 2 (13%) 0.39
Disease Activity
BVAS 4 (1–19) 6 (2.5–12.5) 0.91
Hematocrit 0.39 (0.32–0.41) 0.41 (0.38–0.44) 0.10
Medication
Beta-blockers 5 (24%) 4 (25%) 0.93
ARB 10 (48%) 4 (25%) 0.16
ASA - 5 (31%)
CCB 6 (29%) 2 (13%) 0.24
Statins 1 (5%) 2 (13%) 0.37
Diuretics 4 (19%) 4 (25%) 0.66
Steroids 21 (100%) 16 (100%) 0.16
NSAID 1 (5%) -
Antibodies 2 (10%) -
Cyclophosphamide 11 (52%) 6 (38%) 0.67
Azathioprine 1 (5%) 3 (19%) 0.18
Methotrexate 2 (10%) 3 (19%) 0.42
All values are n (%) or interquartile ranges. CVD cardiovascular disease, BMI
body mass index, ECG electrocardiogram, BVAS Birmingham vasculitis activity
score, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium
channel blockers, NSAID nonsteroidal anti-inflammatory drug
aCurrent or ever-smokers
Table 3 CMR findings
Controls (n = 20) Patients (n = 37) p
LV-EF (%) 65 ± 4 64 ± 10 0.84
LV-EDV (ml) 109 ± 27 122 ± 41 0.38
LV-ESV (ml) 38 ± 13 46 ± 31 0.49
LV-SV 71 ± 15 76 ± 18 0.40
LV-EDD 45 ± 5 48 ± 5 0.08
LA (cm2) 20 ± 3 20 ± 5 0.84
IVS (mm) 10 ± 2 10 ± 2 0.11
PA (mm) 24 ± 4 25 ± 3 0.37
LV mass (g) 85 ± 20 90 ± 25 0.67
LGE - 16 (43%)
epicardial - 5 (13%)
intramural - 7 (19%)
transmural - -
subendocardial - 4 (11%)
% LV mass - 6.8 ± 5
Native T1 (ms) 952 (923–960) 988 (965–1017) <0.001
Post-contrast T1 (ms) 524 (500–529) 488 (468–528) 0.03
ECV (%) 24.5 (23–25) 27.5 (26–29) <0.001
T2 (ms) 49 (48–51) 53 (51–55) <0.001
All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic
resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume,
ESV end-systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left
atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium
enhancement, ECV extracellular volume
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Values above the 95% percentile of normal
Definite abnormal values (beyond the 95% percentile of
controls) were above 987 ms for native T1, below
471 ms for post-contrast T1, above 29% for ECV, and
above 52 ms for T2, Fig. 4.
Fifty-one percent (n = 19) of the AAV patients showed
a native T1 value above the 95% percentile of controls,
with the majority (68%) of them being LGE-negative. In
n = 10 patients, post-contrast values were below 471 ms,
30% of these were LGE-negative. Measurement of ECV
revealed that n = 7 patients had definite abnormal values,
29% LGE-negative. 54% (n = 20) of the AAV patients
showed definite abnormal T2 values, 45% LGE-negative.
Patients with EGPA showed in 40% (9 out of 22 EGPA
patients) an increased native T1 value above the 95%
percentile of controls, 56% LGE-negative. Eight patients
(1 LGE-negative) had post-contrast T1 values lower, and
five patients (all LGE-positive) had ECV values higher
than the 95% percentile of controls. 50% (n = 11) of the
EGPA patients showed definite abnormal T2 values, 36%
were LGE negative.
Patients with GPA showed in 67% (10 out of 15 GPA
patients) increased native T1 values above the 95% per-
centile of controls, with 80% classified as LGE-negative.
Two patients (both LGE-negative) had post-contrast T1
values lower, and two patients (both LGE-negative) had
ECV values higher than the 95% percentile of controls.
60% (9 out of 15 GPA patients) showed definite abnor-
mal T2 values: 56% were LGE negative.
AAV patients with ECG abnormality
In AAV patients with ECG abnormalities (n = 11) func-
tional CMR parameters, LGE prevalence, native and
post-contrast T1 did not differ significantly to patients
with no ECG abnormalities, Table 7. However, ECV and
T2 mapping revealed higher median values in patients
with ECG abnormality (ECV 29%, T2 55 ms) vs. patients
with unremarkable ECG (ECV 26%, T2 52 ms), p = 0.01
and p = 0.009, respectively. 36% of the patients with
ECG abnormalities, and 11% of the patients with normal
ECG showed ECV values above the 95% percentile of
controls. Furthermore, 82% of the patients with ECG
abnormalities (9 out of 11) demonstrated increased
T2 value above the 95% percentile of normal com-
pared to 42% (11 out of 26) of the patients with un-
remarkable ECG.
Discussion
This is the first study evaluating cardiac involvement in
patients with AAV by a CMR protocol, including LGE,
Table 4 CMR findings divided by LGE status
LGE negative (n = 21) LGE positive (n = 16) p
LV-EF (%) 69 ± 7 59 ± 12 0.01
LV-EDV (ml) 117 ± 40 128 ± 44 0.37
LV-ESV (ml) 38 ± 21 56 ± 38 0.06
LV-SV 79 ± 22 72 ± 11 0.43
LV-EDD 47 ± 6 49 ± 4 0.09
LA (cm2) 21 ± 5 20 ± 4 0.54
IVS (mm) 10 ± 2 11 ± 2 0.56
PA (mm) 25 ± 4 25 ± 2 0.75
LV mass (g) 90 ± 25 90 ± 24 0.93
LGE per patient - 16 (100%)
epicardial - 6 (37%)
intramural - 6 (37%)
transmural - -
subendocardial - 4 (25%)
% LV mass - 6.8 ± 5
Native T1 (ms) 1002 (970–1025) 982 (957–998) 0.10
Post-contrast T1 (ms) 501 (478–542) 477 (429–497) 0.04
ECV (%) 27 (25–28) 28 (26–32) 0.13
T2 (ms) 51 (50–55) 54 (52–56) 0.14
All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic
resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume,
ESV end-systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left
atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium
enhancement, ECV extracellular volume
Table 5 CMR findings EGPA
Controls (n = 20) Patients (n = 22) p
LV-EF (%) 65 ± 4 62 ± 12 0.58
LV-EDV (ml) 109 ± 27 124 ± 48 0.38
LV-ESV (ml) 38 ± 13 51 ± 37 0.35
LV-SV 71 ± 15 74 ± 17 0.76
LV-EDD 45 ± 5 48 ± 6 0.06
LA (cm2) 20 ± 3 21 ± 6 0.97
IVS (mm) 10 ± 2 10 ± 2 0.23
PA (mm) 24 ± 4 25 ± 3 0.27
LV mass (g) 85 ± 20 89 ± 25 0.83
LGE per patient - 9 (41%)
epicardial - 3 (14%)
intramural - 2 (9%)
transmural - -
subendocardial - 4 (18%)
% LV mass - 7.1 ± 6
Native T1 (ms) 952 (923–960) 982 (958–1007) 0.003
Post-contrast T1 (ms) 524 (500–529) 481 (462–527) 0.02
ECV (%) 24.5 (23–25) 28 (25–31) <0.001
T2 (ms) 49 (48–51) 53 (50–55) <0.001
All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic
resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume,
ESV end-systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left
atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium
enhancement, ECV extracellular volume
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and T1 and T2 mapping techniques. Major findings are:
1) Patients with AAV show increased native T1, ECV, T2
and decreased post-contrast T1 values compared to con-
trols. 2) These findings are independent of the presence
of LGE for native T1, ECV, and T2. 3) Most significant
differences to healthy controls were detected for native
T1, ECV, and T2. 4) Native T1 and T2 mapping were
the most frequent parameters above the 95% percentile
of controls. 5) AAV patients with ECG abnormality show
higher ECV and T2 values compared to patients with
normal ECG.
Patient characteristics
The majority of patients were middle-aged, and non- to
oligosymptomatic [3, 23]. ECG abnormalities were de-
tected in 30%, and were more common in EGPA pa-
tients than in GPA patients, which concur the results
from another study investigating cardiac involvement in
AAV patients [3].
General CMR results
The mean LV-EF was preserved (64%), and cardiac di-
mensions were similar to the healthy control group,
underlining the necessity of further detailed tissue
characterization. LGE, highly suggestive of myocardial
involvement, was present in almost half of the AAV pa-
tients (43%) in a mainly non-ischemic pattern (epicar-
dial and/or intramural). However, 18% of the EGPA
patients demonstrated the specific subendocardial LGE
pattern, not related to a distinct coronary territory [4, 9].
Hazebroek [3] investigated 50 EGPA and 41 GPA patients
for cardiac involvement and found a prevalence of LGE in
22% of the EGPA, and 19% of the GPA patients. In con-
trast, we observed a higher LGE prevalence of 45% in
EGPA, which is in line with histologic findings [6], and of
25% in the GPA patients. A reason for this discrepancy
might be that the latter study only included patients in
sustained remission (BVAS = 0), whereas our AAV pa-
tients had active disease (BVAS = 5.5).
T1 and ECV results
Native T1 and ECV are supposed to represent myocardial
fibrosis in the absence of edema, infiltration or infarction,
which could be demonstrated by various studies, including
inflammatory cardiomyopathies [14], and rheumatic disor-
ders, such as systemic lupus erythematosus, and rheuma-
toid arthritis [12, 13]. Since post-contrast T1 depends on
renal function, body fat distribution, dose of contrast
agent, and the time delay between application of contrast
agent and measurement of values, there is consensus that
ECV may overcome these limitations by considering the
pre- and post-contrast myocardial and blood T1, and
adjusting for the hematocrit [11, 17]. We observed higher
native T1 and ECV values in AAV patients than in con-
trols, both p < 0.001, Table 3/Fig. 1, supporting data from
other studies in patients with rheumatic disorders [12, 13].
Ntusi et al. [13] demonstrated in patients with rheumatoid
arthritis higher native T1 and ECV compared to controls,
both p < 0.001, matching our results. Furthermore, post-
contrast T1 values were decreased in comparison to con-
trols (p = 0.04), which is another similarity to our AAV
population, p = 0.03. For native T1 and ECV, values of
LGE-positive AAV patients showed no significant dif-
ferences to the values of LGE-negative ANCA pa-
tients (p = 0.10, p = 0.12, respectively), completely in
line with the latter studies [12, 13].
In the EGPA subgroup, patients vs. controls demon-
strated: 1) significantly higher median native T1 (p = 0.003)
and ECV values (p < 0.001), 2) significantly decreased post-
contrast values (p = 0.02). In EGPA, release of toxic me-
diators by activated eosinophils can cause myocardial
alterations, and the presence of myocardial granulomas
might yield scar tissue [23], resulting in a combination
of both inflammation (active phase) and fibrosis (more
chronic phase) [4].
For GPA, we also found increased medians for na-
tive T1 and ECV values in comparison to controls
(both p < 0.001). Similar to EGPA, a combination of
inflammation and fibrosis is suggested for patients
Table 6 CMR findings GPA
Controls (n = 20) Patients (n = 15) p
LV-EF (%) 65 ± 4 68 ± 7 0.24
LV-EDV (ml) 109 ± 27 118 ± 28 0.57
LV-ESV (ml) 39 ± 13 39 ± 14 0.91
LV-SV 71 ± 15 80 ± 20 0.19
LV-EDD 45 ± 5 47 ± 4 0.36
LA (cm2) 20 ± 3 20 ± 3 0.71
IVS (mm) 10 ± 2 11 ± 2 0.11
PA (mm) 24 ± 4 24 ± 4 0.78
LV mass (g) 85 ± 20 92 ± 25 0.57
LGE per patient - 7 (47%)
epicardial - 3 (20%)
intramural - 4 (27%)
transmural - -
subendocardial - -
% LV mass - 6.3 ± 4
Native T1 (ms) 952 (923–960) 1002 (972–1023) <0.001
Post-contrast T1 (ms) 524 (500–529) 490 (477–551) 0.16
ECV (%) 24.5 (23–25) 27 (26–28) <0.001
T2 (ms) 49 (48–51) 53 (51–54) <0.001
All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic
resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume,
ESV end-systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left
atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium
enhancement, ECV extracellular volume
Greulich et al. Journal of Cardiovascular Magnetic Resonance  (2017) 19:6 Page 6 of 12
with GPA [24], which is further underlined by the
finding that values of both AAV subgroups (EGPA vs.
GPA) revealed no significant differences in native T1,
post-contrast T1, and ECV values (p = 0.09, p = 0.32,
p = 0.44, respectively). Moreover, Hazebroek et al. [3]
detected inflammatory states in most of the endomyo-
cardial biopsy specimens of EGPA and GPA patients,
and found no significant difference in interstitial fi-
brosis quantified as collagen volume fraction between
EGPA and GPA (p = 0.91), supporting our results.
T2 results
T2 allows detection of the myocardial free tissue water
content [14], predisposing this technique for detection of
active myocardial inflammation. Inflammation is one of
the hallmarks in patients with systemic vasculitis, indicat-
ing a more acute phase of the disease, which might resolve
after appropriate treatment. In contrast, fibrotic lesions
detected by LGE-CMR tend to represent a more chronic
phase, persisting on follow-up exams [25, 26]. Therefore,
T2 mapping might help to separate myocardial inflamma-
tion from myocardial fibrosis since T2 mapping has
proven to be an objective, precise and reliable method for
the detection of inflammatory conditions [18, 27].
As to expect, we found higher median myocardial T2
values in AAV patients compared to controls, p < 0.001,
Table 3/Fig. 1. Similar to native T1 and ECV, this finding
was independent of the patients’ LGE status, suggesting
an additional gain of information about the patients’ in-
flammatory status compared to the assessment with
LGE-CMR alone.
In the subgroup analysis, T2 values for both EGPA and
GPA patients differed significantly from the T2 values of
the control group (p < 0.001 each), Tables 5 and 6. In
Fig. 1 Box plots for median native T1, post-contrast T1, extracellular volume fraction (ECV), and T2 mapping in: controls, AAV patients, late
gadolinium enhancement (LGE)-negative AAV patients, and LGE-positive AAV patients. The center line in each box represents the median,
whereas the lower and upper limits of each box represent the 25 and 75th percentiles, respectively. Except for post-contrast T1 values
between LGE-negative AAV patients and controls, all other parameters (native T1, post-contrast T1, ECV, and T2) differed significantly to
the values of controls;*: p ≤ 0.05; **: p = ≤0.01, ***: p ≤ 0.001
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contrast, T2 values between both AAV subgroups (EGPA
and GPA) showed no significant difference (p = 0.85).
These results suggest a common pathway of myocardial
involvement in AAV patients, reflecting a combination of
both ongoing inflammation and fibrosis, which is sup-
ported by histology in the literature [3, 25].
Values above the 95% percentile of normal
Despite highly significant differences between patients
and controls, there is some overlap in T1, ECV, and T2
values, which seem to lower the diagnostic accuracy in
the individual AAV patient. Defining the 95% percentile
of the control group as threshold for definite abnormal
Fig. 2 CMR of a 77-year-old female with EGPA (BVAS = 4), presenting with palpitations and atrial fibrillation. Cine images (a) revealed normal
LV-EF (66%), LGE (b) detected intramural enhancement in the inferior septum (white arrows), suggestive of cardiac involvement. Native T1 map (c)
showed increased T1 with 980 ms, shortened post-contrast T1 (d) with 452 ms, increased ECV (e) of 37%, and higher T2 (f) (52 ms) compared
to controls
Fig. 3 CMR of a 26-year-old female with a history of EGPA for 3 years with the same BVAS (=4) as the patient from Fig. 2. She was suffering from
palpitations and dyspnea, ECG was normal. Cine images (a) showed a preserved LV-EF (67%), LGE images (b) were negative. However, native T1
(1019 ms, c), ECV (27%, e), and T2 (52 ms, f) were increased compared to controls, suggesting myocardial involvement despite normal LV-EF, and
unremarkable ECG
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Fig. 4 Values for T1 (native, post-contrast), ECV, and T2 in controls, LGE-negative and LGE-positive EGPA (represented by circles), and GPA
(represented by triangles) patients. The dotted lines represent the thresholds for values beyond the 95% percentile of the control group
(definite abnormal values)
Table 7 CMR findings in patients with normal ECG vs. abnormal ECG
ECG normal (n = 26) ECG abnormal (n = 11) p
LV-EF (%) 66 ± 9 61 ± 12 0.47
LV-EDV (ml) 116 ± 28 136 ± 60 0.68
LV-ESV (ml) 40 ± 17 59 ± 47 0.46
LV-SV 76 ± 17 77 ± 21 0.79
LV-EDD 47 ± 5 49 ± 6 0.31
LA (cm2) 19 ± 3 23 ± 7 0.16
IVS (mm) 10 ± 2 11 ± 2 0.06
PA (mm) 25 ± 3 25 ± 4 0.80
LV mass (g) 91 ± 23 89 ± 30 0.46
LGE positive (n) 10 (39%) 6 (55%) 0.37
Native T1 (ms) 983 (960–1010) 1006 (983–1037) 0.11
Post-contrast T1 (ms) 487 (464–538) 490 (476–512) 0.62
ECV (%) 26 (25–28) 29 (28–32) 0.01
T2 (ms) 52 (50–54) 55 (53–57) 0.009
All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume, ESV end-
systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium enhancement,
ECV extracellular volume
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values, we found native T1 and T2 to be the most fre-
quent values: 51% (n = 19) of the AAV patients showed a
native T1 value above the 95% percentile of the control
group, with the majority (68%) of them reported LGE-
negative, suggesting potential diagnostic value in pa-
tients with no overt cardiac involvement. 54% (n = 20) of
the AAV patients showed definite abnormal T2 values,
with 45% LGE-negatives, underscoring that increased T2
values are not driven by the presence of LGE alone.
Although the patients’ disease activity (BVAS) did not
correlate to the mapping values in our study, GPA pa-
tients demonstrated compared to EGPA patients: 1)
higher BVAS (11.5 vs. 5), and 2) higher percentage of pa-
tients with abnormal values beyond the 95% percentile
of normal, potentially reflecting higher disease activity.
However, it must be noted that myocardial involvement
may be the initial manifestation of AAV, which might be
subclinical in early stages.
AAV patients with ECG abnormality
AAV patients with ECG abnormalities showed signifi-
cantly increased ECV values, but not a significantly higher
prevalence of LGE compared to patients with normal
ECG, p = 0.01, p = 0.37, respectively. Therefore, increased
ECV values may reflect diffuse fibrosis (in addition to focal
fibrosis detected by LGE-CMR), potentially yielding ECG
abnormalities. In a recent study [28], histological ECV of
left-ventricular specimens was significantly correlated with
CMR-ECV (r = 0.493, p = 0.002). Of note, patients with
higher ECV demonstrated a higher prevalence of ECG ab-
normalities (p < 0.001), supporting our findings.
Additionally, patients with ECG abnormalities showed
higher T2 values than patients without ECG abnormal-
ities (p = 0.009), which is a similarity to a study per-
formed in patients with sarcoidosis [29]. Of note, 82% of
the patients with ECG abnormalities in our study dem-
onstrated increased T2 value above the 95% percentile
of normal. Since increased T2 values, as a substrate of
inflammation, are supposed to represent potentially re-
versible processes [29], T2 mapping might serve as an
appropriate quantitative biomarker during the clinical
course of inflammatory disease such as AAV.
Clinical implications
Our data demonstrate that patients with AAV (EGPA
and GPA) show several abnormalities detected by
CMR mapping techniques. Interestingly, most patients
were non- or oligosymptomatic, had normal ECG,
and a preserved LV-EF, suggesting an incremental
value of mapping techniques in the assessment of
subclinical myocardial involvement in early, poten-
tially reversible stages of AAV, which might have been
missed otherwise. Since native T1, ECV, and T2
values were independent from the presence of LGE,
these parameters seem to provide complementary in-
formation about diffuse myocardial involvement com-
pared to LGE alone. Most significant differences
(beyond the 95% percentile of controls) were observed
for native T1 and T2, suggesting a combination of
both chronic (fibrosis) and acute (inflammation)
stages in AAV patients.
Our findings suggest that recent T1 and T2 mapping
techniques might play a role in patients with AAV for: 1)
detection of even subtle myocardial involvement, 2) as-
sessment of different stages of the disease (acute vs.
chronic), 3) decision-making about subsequent medical
therapy, preventing progression of further cardiac dam-
age, and 4) the evaluation of response to treatment dur-
ing follow-up.
Limitations
Since this is a single-center study, potential center-
specific bias cannot be excluded. The measurement of
global myocardial T1 or T2 values in a single mid-
ventricular slice might miss a focal process due to “aver-
aged” values. However, this approach is common prac-
tice [30], less subjective than individualized regions of
interest, and might be better comparable to potential
follow-up exams.
Endomyocardial biopsy (EMB) was not routinely per-
formed. However, it is known that EMB has several limi-
tations, lowering its diagnostic benefit. Furthermore, in
non- to oligosymptomatic patients with preserved LV-EF
and negative LGE-CMR, this would be a rather unethical
approach.
Whether abnormalities by T1 and T2 mapping in pa-
tients with AAV represent myocardial involvement
should be evaluated by further studies, including EMB.
However, T1 and T2 mapping seem to be appropriate
techniques, since a combination of both inflammation
and fibrosis could be detected by histology in other stud-
ies with AAV patients [3, 25].
Conclusions
In patients with AAV (EGPA and GPA), we found higher
values for native T1, ECV, and T2 compared to controls,
irrespective of the presence of LGE. Native T1 and T2,
assessing diffuse fibrotic and inflammatory myocardial
changes, were the most frequent parameters showing
values beyond the 95% percentile of controls. Therefore,
they seem to be the most promising techniques for the
early detection of myocardial involvement in potential
reversible stages.
However, further studies are needed, elucidating the
role of mapping techniques in diagnosis and monitoring
of myocardial involvement in patients with AAV.
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